Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2011
At a glance
- Drugs Mesothelin SS dsFv PE38 (Primary)
- Indications Cervical cancer; Head and neck cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2008 'National Cancer Institute - Center for Cancer Research-Medical Oncology' added as study sponsor as reported by ClinicalTrials.gov.
- 15 Aug 2005 New trial record.